

14. TABLES, FIGURES AND GRAPHS REFERRED TO BUT NOT INCLUDED IN THE TEXT

14.1 Demographic Data

TSIDM01: Summary of Demographics and Baseline Disease Characteristics; Intent-to-Treat Analysis Set (Study GRN163LMYF3001)2

TSIDS01: Treatment Disposition and Reasons for Discontinuation from Treatment; Treated Analysis Set (Study GRN163LMYF3001)4

14.3 Safety Data

FEFOS01A: Kaplan-Meier Plot of Overall Survival; Intent-to-treat Analysis Set (Study GRN163LMYF3001)5

TSIDM01: Summary of Demographics and Baseline Disease Characteristics; Intent-to-Treat Analysis Set (Study GRN163LMYF3001)

	Dummy Imetelstat (N=180)	Dummy BAT (N=90)	Total (N=270)
Age (years)			
n	180	90	270
< 65	69 (38.3%)	29 (32.2%)	98 (36.3%)
>= 65	111 (61.7%)	61 (67.8%)	172 (63.7%)
< 75	144 (80.0%)	70 (77.8%)	214 (79.3%)
>= 75	36 (20.0%)	20 (22.2%)	56 (20.7%)
Mean (SD)	65.6 (10.48)	67.9 (8.36)	66.4 (9.87)
Median	68.0	69.5	68.0
Range	(25, 85)	(41, 83)	(25, 85)
Sex			
n	180	90	270
Male	100 (55.6%)	61 (67.8%)	161 (59.6%)
Female	80 (44.4%)	29 (32.2%)	109 (40.4%)
Childbearing potential?			
Yes	8 (10.0%)	1 (3.4%)	9 (8.3%)
No	72 (90.0%)	28 (96.6%)	100 (91.7%)
Region			
n	180	90	270
North America	15 (8.3%)	4 (4.4%)	19 (7.0%)
European Union	70 (38.9%)	34 (37.8%)	104 (38.5%)
Rest Of World	93 (51.7%)	51 (56.7%)	144 (53.3%)
Missing	2 (1.1%)	1 (1.1%)	3 (1.1%)
Ethnicity			
n	180	90	270
Hispanic or Latino	15 (8.3%)	14 (15.6%)	29 (10.7%)
Not Hispanic or Latino	150 (83.3%)	69 (76.7%)	219 (81.1%)
Unknown	3 (1.7%)	3 (3.3%)	6 (2.2%)
Not reported	12 (6.7%)	4 (4.4%)	16 (5.9%)
Race			
n	180	90	270
American Indian or Alaska Native	2 (1.1%)	3 (3.3%)	5 (1.9%)
Asian	38 (21.1%)	17 (18.9%)	55 (20.4%)
Black or African American	1 (0.6%)	0	1 (0.4%)
Native Hawaiian or other Pacific Islander	0	0	0
White	125 (69.4%)	65 (72.2%)	190 (70.4%)
Other	4 (2.2%)	1 (1.1%)	5 (1.9%)
Multiple	0	1 (1.1%)	1 (0.4%)
Unknown	2 (1.1%)	0	2 (0.7%)
Not reported	8 (4.4%)	3 (3.3%)	11 (4.1%)

TSIDM01: Summary of Demographics and Baseline Disease Characteristics; Intent-to-Treat Analysis Set (Study GRN163LMYF3001)

	Dummy Imetelstat (N=180)	Dummy BAT (N=90)	Total (N=270)
Weight (kg)			
n	180	90	270
Mean (SD)	70.38 (15.223)	71.39 (15.096)	70.71 (15.160)
Median	69.00	70.00	69.00
Range	(42.0, 143.7)	(40.0, 124.0)	(40.0, 143.7)
Height (cm)			
n	174	89	263
Mean (SD)	167.16 (9.555)	169.36 (8.866)	167.91 (9.369)
Median	167.15	170.00	168.00
Range	(140.0, 198.0)	(144.4, 188.0)	(140.0, 198.0)
BMI (kg/m ²)			
n	174	89	263
Mean (SD)	24.93 (4.116)	24.72 (4.521)	24.86 (4.250)
Median	24.14	24.36	24.34
Range	(16.1, 46.9)	(15.7, 40.0)	(15.7, 46.9)

Key: n = the number of subjects in each group with non-missing parameter values; BAT = Best Available Therapy; BMI = Body Mass Index; SD = Standard Deviation.

Percentages are calculated with the number of subjects in each group with non-missing parameter values as denominator.

Percentage for the category Childbearing potential is calculated from the subjects in female group with non-missing parameter values as the denominator.

[\\vc01\biometrics\GRN163L_imetelstat\MYF3001\DB_IADryRun\RE_IADryRun\Preprod\PROGRAM\tsidm01.sas] 23APR2025, 20:49
Database Extract Date: 01apr2025; Cut-off Date: 2025-04-01

**TSIDS01: Treatment Disposition and Reasons for Discontinuation from Treatment; Treated Analysis Set
(Study GRN163LMYF3001)**


	Randomized		Dummy Crossover Imetelstat (N=15)	Dummy Imetelstat Total (N=191)
	Dummy Imetelstat (N=176)	Dummy BAT (N=85)		
Subjects treatment ongoing	63 (35.8%)	26 (30.6%)	6 (40.0%)	69 (36.1%)
Subjects who discontinued the treatment	113 (64.2%)	59 (69.4%)	9 (60.0%)	122 (63.9%)
Reason for discontinuation				
Withdrawal by subject	39 (22.2%)	15 (17.6%)	1 (6.7%)	40 (20.9%)
Progressive disease	29 (16.5%)	18 (21.2%)	2 (13.3%)	31 (16.2%)
Adverse event	11 (6.3%)	6 (7.1%)	3 (20.0%)	14 (7.3%)
Lack of efficacy	14 (8.0%)	8 (9.4%)	0	14 (7.3%)
Physician decision	10 (5.7%)	6 (7.1%)	2 (13.3%)	12 (6.3%)
Death	5 (2.8%)	3 (3.5%)	1 (6.7%)	6 (3.1%)
COVID-19	0	0	0	0
Lost to follow-up	0	0	0	0
Non-compliance with study drug	0	0	0	0
Pregnancy	0	0	0	0
Product quality complaint	0	0	0	0
Protocol violation	0	0	0	0
Study terminated by sponsor	0	0	0	0
Other	4 (2.3%)	3 (3.5%)	0	4 (2.1%)

Key: BAT = Best Available Therapy.

Percentages are calculated with the number of subjects in each treatment group as the denominators.

[\\vc01\biometrics\GRN163L_imetelstat\MYF3001\DB_IADryRun\RE_IADryRun\Preprod\PROGRAM\tsids01.sas] 23APR2025, 20:49
Database Extract Date: 01apr2025; Cut-off Date: 2025-04-01

FEFOS01A: Kaplan-Meier Plot of Overall Survival; Intent-to-treat Analysis Set (Study GRN163LMYF3001)



Number of Subjects at Risk

Dummy Imetelstat	180	140	103	68	49	31	19	4	0
Dummy BAT	90	71	51	37	22	15	8	1	0